Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

James Brugarolas, ASCO 2019 – Advances in sarcomatoid RCC

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 11th 2019

At the ASCO 2019 annual meeting, James Brugarolas discusses sarcomatoid renal cell carcinoma, the current challenges and the advances that are defining a new treatment paradigm.

Questions

1. What is sarcomatoid renal cell carcinoma (RCC) and what is its prognosis? (0:04)
2. What are the major treatment challenges in sarcomatoid RCC? (0:54)
3. Why is sarcomatoid RCC particularly responsive to immune checkpoint blockade? (1:40)
4. What is the impact on patient survival? (2:45)
5. What further data are needed for checkpoint inhibitors to become the standard of care in sarcomatoid RCC? (3:11)

Speaker disclosure: James Brugarolas has nothing to disclosure in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup